THE NEURODEGENERATIVE RISKS IN PSORIASIS: A REVIEW ON ALZHEIMER’S DISEASE IN PSORIATIC PATIENTS

Tóm tắt

Psoriasis is a persistent inflammatory condition that impacts 2-3% of individuals worldwide and has recently been associated with a heightened risk of neurodegenerative diseases, particularly Alzheimer’s disease. This review examines the common pathophysiological mechanisms linking psoriasis and atopic dermatitis, indicating that chronic inflammation, immune dysregulation, and oxidative stress could play a role in neurodegeneration and cognitive decline among individuals with psoriasis. Inflammatory substances like tumor necrosis factor-alpha (TNF-α) and interleukin17, which are found at increased levels in psoriasis, have the ability to penetrate the blood-brain barrier and trigger neuroinflammatory processes in the central nervous system. This may contribute to the earlier onset and advancement of Alzheimer's disease. This study initiates with an examination of epidemiological data indicating a greater occurrence of Alzheimer's disease in individuals with psoriasis compared to the broader population. This establishes a fundamental connection. An indepth analysis of the underlying mechanisms is presented, emphasizing the role of inflammatory cytokines, microglial activation, and oxidative stress in the pathology of psoriasis and the associated risk of Alzheimer's disease. This study examines genetic and epigenetic elements, including polymorphisms that influence immune regulation, to elucidate the increased susceptibility observed in individuals with psoriasis. Therapeutic techniques are also considered. The use of antiinflammatory agents, especially TNF-α and interleukin-17 inhibitors commonly prescribed for psoriasis, may play a role in regulating systemic inflammation and potentially lowering the risk of Alzheimer's disease. Furthermore, neuroprotective approaches, such as antioxidant therapy and lifestyle changes, are being investigated for their potential to reduce the risk of neurodegenerative diseases by addressing oxidative damage and inflammation. Recent studies on molecular targets such as ZNF384 and innovative therapeutic approaches offer encouraging prospects for personalized treatments designed to address the unique genetic and inflammatory characteristics of psoriasis patients who may be at risk for Alzheimer's disease. This review highlights the importance of a collaborative strategy in addressing psoriasis and atopic dermatitis, indicating that prompt treatment and specific therapies can lead to better long-term health results and improve the quality of life for those dealing with these intricate health issues.